What is the Daehan New Pharm Co., Ltd. stock price forecast?

Daehan New Pharm Co., Ltd. is currently trading at ₩5,840. View real-time AI analysis on Alpha Lenz.

What is Daehan New Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Daehan New Pharm Co., Ltd. on Alpha Lenz.

What is Daehan New Pharm Co., Ltd.'s P/E ratio?

Daehan New Pharm Co., Ltd.'s P/E ratio is 5.5.

Daehan New Pharm Co., Ltd.

KRX · 054670

₩5,840+30(+0.52%)Market closed

Ask about Daehan New Pharm Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Daehan New Pharm Co., Ltd. trades at a P/E of 5.5 (undervalued) with solid ROE of 11.5%.”

Ask for details →

Company Overview

Daehan New Pharm Co., Ltd. is a South Korean company involved in the pharmaceutical industry, focusing on the development and distribution of innovative healthcare solutions. As a key player in the pharmaceutical sector, Daehan New Pharm is dedicated to advancing medical research and producing a diverse range of pharmaceutical products that contribute to the improvement of public health. The company's portfolio includes various medications aimed at treating a spectrum of health conditions, underscoring its commitment to health and wellness enhancements. Operating within a highly competitive and vital industry, Daehan New Pharm collaborates with healthcare professionals and institutions to ensure that its products meet the highest standards of efficacy and safety. Through its efforts, Daehan New Pharm Co., Ltd. plays a crucial role in the South Korean pharmaceutical market, fostering advancements in the country's healthcare system.

CEO이원석

Websitehttps://www.dhnp.co.kr

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees228

Company Statistics

FY 2025

Profile

₩83,832,732,800Market Cap

₩202,401,496,490Revenue

14.35MShares Out

228Employees

Margins

45.58%Gross

8.33%EBITDA

5.79%Operating

7.40%Pre-Tax

7.54%Net

Valuation

5.49P/E

0.60P/B

0.41EV/Sales

9.66EV/EBITDA

-1.82P/FCF

Growth (CAGR)

0.74%Rev 3Yr

6.28%Rev 5Yr

-31.50%Op Inc 3Yr

-6.71%Op Inc 5Yr

-14.39%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

6.20%ROA

11.50%ROE

6.76%ROIC

Financial Health

₩19,966,370,550Cash & Cash Equivalents

₩111,268,842,560Net Debt

93.77%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Daehan New Pharm Co., Ltd. trades at a P/E of 5.5 (undervalued) with solid ROE of 11.5%.”

Ask for details →

Frequently Asked Questions

Daehan New Pharm Co., Ltd. (ticker: 054670) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 228 employees. Market cap is $83.8B.

The current price is ₩5,840 with a P/E ratio of 5.49x and P/B of 0.6x.

ROE is 11.50% and operating margin is 5.79%. Annual revenue is $202.4B.